TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Trial of the Effect of Exercise on Peripheral Blood Gene Expression in Patients With Stable Angina
Brief Summary: Regular exercise is known to produce significant health benefits and to reduce the risk of heart diseases, although how this benefit occurs is not well understood. White blood cells are known to be involved in triggering heart attacks, and which genes are switched on or off in white blood cells determines whether they have beneficial or harmful effects. Previous studies, and studies ongoing in our group, have demonstrated measurement of peripheral blood gene expression (which reflects white blood cell gene expression) is able to distinguish between patients with and without coronary artery disease, or patients who are able to develop good compared with poor coronary collateral arteries. Therefore, the gene expression signature in peripheral blood may provide novel diagnostic or prognostic information, and insight into the pathogenesis of heart disease.

We therefore hypothesise that exercise alters peripheral blood gene expression in patients with coronary artery disease and angina. This will identify possible ways that exercise improves angina and reduces the risk of heart disease.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise training | Arm Label: intensive exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive exercise training | Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): Exercise training | Intervention Type: BEHAVIORAL; Name: Intensive exercise training; Assigned to Arm(s): intensive exercise training
B: Arm Label: 12 week exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Structured exercise training | Arm Label: Conventional Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Structured exercise training; Assigned to Arm(s): 12 week exercise training
C: Arm Label: Center-based cardiac rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Center-based cardiac rehabilitation | Arm Label: Home-based training with telemonitoring guidance; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based training with telemonitoring guidance | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Center-based cardiac rehabilitation; Assigned to Arm(s): Center-based cardiac rehabilitation | Intervention Type: BEHAVIORAL; Name: Home-based training with telemonitoring guidance; Assigned to Arm(s): Home-based training with telemonitoring guidance
D: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Exercise-based cardiac rehabilitation program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise-based cardiac rehabilitation program; Assigned to Arm(s): Experimental group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Trial of the Effect of Exercise on Peripheral Blood Gene Expression in Patients With Stable Angina
Brief Summary: Regular exercise is known to produce significant health benefits and to reduce the risk of heart diseases, although how this benefit occurs is not well understood. White blood cells are known to be involved in triggering heart attacks, and which genes are switched on or off in white blood cells determines whether they have beneficial or harmful effects. Previous studies, and studies ongoing in our group, have demonstrated measurement of peripheral blood gene expression (which reflects white blood cell gene expression) is able to distinguish between patients with and without coronary artery disease, or patients who are able to develop good compared with poor coronary collateral arteries. Therefore, the gene expression signature in peripheral blood may provide novel diagnostic or prognostic information, and insight into the pathogenesis of heart disease.

We therefore hypothesise that exercise alters peripheral blood gene expression in patients with coronary artery disease and angina. This will identify possible ways that exercise improves angina and reduces the risk of heart disease.


Options:
A: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A
B: Arm Label: 12 week exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Structured exercise training | Arm Label: Conventional Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Structured exercise training; Assigned to Arm(s): 12 week exercise training
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Prehab Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Prehab Intervention | Intervention Type: BEHAVIORAL; Name: Prehab Intervention; Assigned to Arm(s): Prehab Intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Patient as a Driver of Change: an Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults
Brief Summary: An educational intervention targeting community-dwelling older adults will lead to a reduction in potentially inappropriate prescriptions (e.g. benzodiazepines, oxybutynin).

Cessation of potentially inappropriate medications (e.g. benzodiazepines, oxybutynin)will lead to improved cognitive outcomes in older adults.


Options:
A: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Behavioral: knowledge transfer tool | Arm Label: Wait-list group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: knowledge transfer tool; Assigned to Arm(s): Educational intervention
B: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care
C: Arm Label: PHCVRS intervention; Type: EXPERIMENTAL; Interventions: Other: PHCVRS Intervention, Other: Personal Health Record | Arm Label: Usual care/Personal Health Record; Type: OTHER; Interventions: Other: Personal Health Record | Intervention Type: OTHER; Name: PHCVRS Intervention; Assigned to Arm(s): PHCVRS intervention | Intervention Type: OTHER; Name: Personal Health Record; Assigned to Arm(s): PHCVRS intervention, Usual care/Personal Health Record
D: Arm Label: Pharmaceutical Education; Type: EXPERIMENTAL; Interventions: Behavioral: Education interventional | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Education interventional; Assigned to Arm(s): Pharmaceutical Education

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Patient as a Driver of Change: an Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults
Brief Summary: An educational intervention targeting community-dwelling older adults will lead to a reduction in potentially inappropriate prescriptions (e.g. benzodiazepines, oxybutynin).

Cessation of potentially inappropriate medications (e.g. benzodiazepines, oxybutynin)will lead to improved cognitive outcomes in older adults.


Options:
A: Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Interdisciplinary collaboration structure | Intervention Type: OTHER; Name: Interdisciplinary collaboration structure; Assigned to Arm(s): Intervention
B: Arm Label: Optimization of drug prescribing; Type: EXPERIMENTAL; Interventions: Other: Optimization of drug prescribing | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Optimization of drug prescribing; Assigned to Arm(s): Optimization of drug prescribing
C: Intervention Type: BEHAVIORAL; Name: Opinion leader generated and endorsed evidence summaries; Assigned to Arm(s): N/A
D: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Behavioral: knowledge transfer tool | Arm Label: Wait-list group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: knowledge transfer tool; Assigned to Arm(s): Educational intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interaction of Orally Administered Lactobacillus Rhamnosus GG With Skin and Gut Microbiota and Humoral Immunity in Infants With Atopic Dermatitis
Brief Summary: Hypothesis: Probiotics have been used as novel adjunct therapeutic approach in atopic dermatitis. In addition to balancing the gut microecology and promoting host immune defences, specific probiotics might further aid in controlling the microbial colonization of the skin, thereby reducing proneness to secondary infections which typically cause sustained symptoms.

Thirty-nine infants with atopic dermatitis,randomized for a three-month-period in a double-blind design to receive extensively hydrolysed casein formula (NutramigenR, Mead-Johnson, USA) supplemented with (n=19) or without (n=20) Lactobacillus rhamnosus GG (ATCC 53103) 5.0 x 107 cfu/g to achieve a daily intake of 3.4 x 109 cfu.

Sampling (blood and faecal samples, cotton swab from the skin) and clinical examination of the infant, including SCORAD assessment to determine the severity of atopic dermatitis, at each study visit (at entry and one month and three months thereafter).


Options:
A: Arm Label: Infants drink formula added with LGG; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Casein hydrolysate added with LGG | Arm Label: Infants drink casein hydrolysate without LGG; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Infants drink casein hydrolysate without LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Casein hydrolysate added with LGG; Assigned to Arm(s): Infants drink formula added with LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Infants drink casein hydrolysate without LGG; Assigned to Arm(s): Infants drink casein hydrolysate without LGG
B: Arm Label: LP GMNL-133 group; Type: EXPERIMENTAL; Interventions: Biological: LP GMNL-133 capsule | Arm Label: LF GM-090 group; Type: EXPERIMENTAL; Interventions: Biological: LF GM-090 capsule | Arm Label: LP GMNL-133+LF GM-090 group; Type: EXPERIMENTAL; Interventions: Biological: LP GMNL-133 +LF GM-090 capsule | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: LP GMNL-133 capsule; Assigned to Arm(s): LP GMNL-133 group | Intervention Type: BIOLOGICAL; Name: LF GM-090 capsule; Assigned to Arm(s): LF GM-090 group | Intervention Type: BIOLOGICAL; Name: LP GMNL-133 +LF GM-090 capsule; Assigned to Arm(s): LP GMNL-133+LF GM-090 group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: probiotics & allergy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus rhamnosus GG | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus rhamnosus GG; Assigned to Arm(s): probiotics & allergy
D: Intervention Type: DRUG; Name: Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Finding the M.I.N.C. for Mammography Maintenance
Brief Summary: RATIONALE: Mammography reminders may encourage women to undergo regular mammography screenings for breast cancer.

PURPOSE: This randomized clinical trial is studying three different mammography reminder interventions to compare how well they work in encouraging women to undergo regular mammography screenings for breast cancer.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: IVR based cognitive behavioral therapy | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Face to face cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: Face to face cognitive behavior therapy; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: IVR based cognitive behavioral therapy; Assigned to Arm(s): Arm 1
B: Arm Label: Standard care; Type: OTHER; Interventions: Behavioral: Standard Care | Arm Label: Sustained Care; Type: EXPERIMENTAL; Interventions: Behavioral: Sustained Care | Intervention Type: BEHAVIORAL; Name: Sustained Care; Assigned to Arm(s): Sustained Care | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard care
C: Arm Label: Automated Telephone Outreach; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Telephone Outreach with Speech Recognition | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Automated Telephone Outreach with Speech Recognition; Assigned to Arm(s): Automated Telephone Outreach
D: Intervention Type: BEHAVIORAL; Name: Mammography appointment reminders; telephone counseling; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study of Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib in Unresectable, Metastatic Biliary Tract Carcinoma
Brief Summary: The purpose of this study is to determine whether Gemcitabine/Oxaliplatin (GEMOX) with or without Erlotinib (Tarceva) is effective in the treatment of unresectable, metastatic biliary tract carcinoma.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemox, Cetuximab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Gemox, Cetuximab | Intervention Type: DRUG; Name: Gemox, Cetuximab; Assigned to Arm(s): 1, 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: ZD6474, Vandetanib | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: ZD6474, Vandetanib, Drug: Gemcitabine | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Placebo matching ZD6474 | Intervention Type: DRUG; Name: ZD6474, Vandetanib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ZD6474, Vandetanib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): B, C | Intervention Type: DRUG; Name: Placebo matching ZD6474; Assigned to Arm(s): C
C: Arm Label: Gemcitabine/Oxaliplatin with Erlotinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine/Oxaliplatin with Erlotinib (Tarceva) | Arm Label: Gemcitabine/Oxaliplatin without Erlotinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine/Oxaliplatin | Intervention Type: DRUG; Name: Gemcitabine/Oxaliplatin; Assigned to Arm(s): Gemcitabine/Oxaliplatin without Erlotinib | Intervention Type: DRUG; Name: Gemcitabine/Oxaliplatin with Erlotinib (Tarceva); Assigned to Arm(s): Gemcitabine/Oxaliplatin with Erlotinib
D: Arm Label: GEMOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine, oxaliplatin | Arm Label: E-GEMOX; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, gemcitabine, oxaliplatin | Intervention Type: DRUG; Name: gemcitabine, oxaliplatin; Assigned to Arm(s): GEMOX | Intervention Type: DRUG; Name: cetuximab, gemcitabine, oxaliplatin; Assigned to Arm(s): E-GEMOX

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The ideal mean arterial pressure in patients with septic shock is unknown. The expert's recommandations have stated a target between 65 and 70 mm Hg. However the scientific basis are weak. Indead there are only few prospective studies which addressed this question without clear answer. Therefore we designed a RCT in order to assess the effect on mortality of two levels of mean arterial pressure in patients with septic shock.(800 patients, 30 centres)


Options:
A: Arm Label: Restrictive transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Transfusion Strategy | Arm Label: Liberal transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal transfusion strategy | Intervention Type: OTHER; Name: Restrictive Transfusion Strategy; Assigned to Arm(s): Restrictive transfusion strategy | Intervention Type: OTHER; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal transfusion strategy
B: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
C: Arm Label: high pressure; Type: ACTIVE_COMPARATOR; Interventions: Drug: maintain mean arterial pressure between 80-85 mm Hg | Arm Label: normal pressure; Type: PLACEBO_COMPARATOR; Interventions: Other: maintain mean arterial pressure between 65-70 mm Hg | Intervention Type: DRUG; Name: maintain mean arterial pressure between 80-85 mm Hg; Assigned to Arm(s): high pressure | Intervention Type: OTHER; Name: maintain mean arterial pressure between 65-70 mm Hg; Assigned to Arm(s): normal pressure
D: Arm Label: IV acetaminophen & IV propofol; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV propofol | Arm Label: IV acetaminophen & IV dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV dexmedetomidine | Arm Label: IV propofol & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV propofol & placebo | Arm Label: IV dexmedetomidine & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV dexmedetomidine & placebo | Intervention Type: DRUG; Name: IV acetaminophen & IV propofol; Assigned to Arm(s): IV acetaminophen & IV propofol | Intervention Type: DRUG; Name: IV acetaminophen & IV dexmedetomidine; Assigned to Arm(s): IV acetaminophen & IV dexmedetomidine | Intervention Type: DRUG; Name: IV propofol & placebo; Assigned to Arm(s): IV propofol & placebo | Intervention Type: DRUG; Name: IV dexmedetomidine & placebo; Assigned to Arm(s): IV dexmedetomidine & placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The ideal mean arterial pressure in patients with septic shock is unknown. The expert's recommandations have stated a target between 65 and 70 mm Hg. However the scientific basis are weak. Indead there are only few prospective studies which addressed this question without clear answer. Therefore we designed a RCT in order to assess the effect on mortality of two levels of mean arterial pressure in patients with septic shock.(800 patients, 30 centres)


Options:
A: Arm Label: Dopamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dopamine | Arm Label: Norepinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Norepinephrine | Intervention Type: DRUG; Name: Dopamine; Assigned to Arm(s): Dopamine | Intervention Type: DRUG; Name: Norepinephrine; Assigned to Arm(s): Norepinephrine
B: Arm Label: continuous terlipressin; Type: EXPERIMENTAL; Interventions: Drug: continuous infusion of terlipressin | Arm Label: vasopressin; Type: EXPERIMENTAL; Interventions: Drug: Arginine vasopressin | Arm Label: terlipressin bolus dose; Type: EXPERIMENTAL; Interventions: Drug: terlipressin bolus administration | Intervention Type: DRUG; Name: continuous infusion of terlipressin; Assigned to Arm(s): continuous terlipressin | Intervention Type: DRUG; Name: Arginine vasopressin; Assigned to Arm(s): vasopressin | Intervention Type: DRUG; Name: terlipressin bolus administration; Assigned to Arm(s): terlipressin bolus dose
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early Goal Directed Therapy; Type: EXPERIMENTAL; Interventions: Other: Early Goal Directed Therapy (EGDT) | Intervention Type: OTHER; Name: Early Goal Directed Therapy (EGDT); Assigned to Arm(s): Early Goal Directed Therapy
D: Arm Label: high pressure; Type: ACTIVE_COMPARATOR; Interventions: Drug: maintain mean arterial pressure between 80-85 mm Hg | Arm Label: normal pressure; Type: PLACEBO_COMPARATOR; Interventions: Other: maintain mean arterial pressure between 65-70 mm Hg | Intervention Type: DRUG; Name: maintain mean arterial pressure between 80-85 mm Hg; Assigned to Arm(s): high pressure | Intervention Type: OTHER; Name: maintain mean arterial pressure between 65-70 mm Hg; Assigned to Arm(s): normal pressure

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Behavioral Therapy in Primary Care: Treating the Medically Ill
Brief Summary: The current study seeks to test the effectiveness of a talk-therapy intervention designed to better meet the needs of chronically ill Veterans. This project looks to recruit 450 Veterans with either chronic obstructive pulmonary disease (COPD) or heart failure (HF) who also have symptoms of worry, stress, anxiety, or sadness. Participants will be randomly put into either the talk-therapy intervention or enhanced usual care.

The talk therapy intervention will be provided by VA clinicians in the primary care setting and will consist of 6 core meetings (30-45 minutes in duration) and 2 follow-up telephone meetings. Enhanced usual care participants will receive feedback regarding the assessment findings and educational materials on COPD and/or HF, depression and anxiety.


Options:
A: Arm Label: CHF patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: COPD patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: CHF patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COPD patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IVR-Enhanced Care; Assigned to Arm(s): CHF patients, IVR-Enhanced Care, COPD patients, IVR-Enhanced Care
B: Arm Label: Disease management program; Type: EXPERIMENTAL; Interventions: Other: Disease Management | Arm Label: Usual site management; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual site management | Intervention Type: OTHER; Name: Disease Management; Assigned to Arm(s): Disease management program | Intervention Type: OTHER; Name: Usual site management; Assigned to Arm(s): Usual site management
C: Arm Label: ACCESS; Type: EXPERIMENTAL; Interventions: Behavioral: ACCESS | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACCESS; Assigned to Arm(s): ACCESS
D: Arm Label: Urban training Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Urban training | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Urban training; Assigned to Arm(s): Urban training Intervention

Answer: C